DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation
Cell Stem Cell
MetadataShow full item record
Farlik, M., Halbritter, F., Müller, F., Choudry, F., Ebert, P., Klughammer, J., Farrow, S., et al. (2016). DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation. Cell Stem Cell, 19 (6), 808-822. https://doi.org/10.1016/j.stem.2016.10.019
Hematopoietic stem cells give rise to all blood cells in a differentiation process that involves widespread epigenome remodeling. Here we present genome-wide reference maps of the associated DNA methylation dynamics. We used a meta-epigenomic approach that combines DNA methylation profiles across many small pools of cells and performed single-cell methylome sequencing to assess cell-to-cell heterogeneity. The resulting dataset identified characteristic differences between HSCs derived from fetal liver, cord blood, bone marrow, and peripheral blood. We also observed lineage-specific DNA methylation between myeloid and lymphoid progenitors, characterized immature multi-lymphoid progenitors, and detected progressive DNA methylation differences in maturing megakaryocytes. We linked these patterns to gene expression, histone modifications, and chromatin accessibility, and we used machine learning to derive a model of human hematopoietic differentiation directly from DNA methylation data. Our results contribute to a better understanding of human hematopoietic stem cell differentiation and provide a framework for studying blood-linked diseases.
DNA methylation profiling, bioinformatic lineage reconstruction, cell type prediction, hematopoietic stem cell differentiation, immature lymphoid progenitors, lymphoid-myeloid lineage commitment, megakaryocyte maturation, reference epigenome mapping, single-cell sequencing, whole genome bisulfite sequencing
This work was funded by the BLUEPRINT project (European Union’s Seventh Framework Programme grant 282510), the NIHR Cambridge Biomedical Research Centre, and the Austrian Academy of Sciences. F.A.C. is supported by a Medical Research Council Clinical Training Fellowship (grant MR/K024043/1). F.H. is supported by a postdoctoral fellowship of the German Research Council (DFG; grant HA 7723/1-1). J.K. is supported by a DOC Fellowship of the Austrian Academy of Sciences. W.H.O. is supported by the NIHR, BHF (grants PG-0310-1002 and RG/09/12/28096), and NHS Blood and Transplant. E.L. is supported by a Wellcome Trust Sir Henry Dale Fellowship (grant 107630/Z/15/Z) and core support grant from the Wellcome Trust and MRC to the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. M. Frontini is supported by the BHF Cambridge Centre of Excellence (grant RE/13/6/30180). C.B. is supported by a New Frontiers Group award of the Austrian Academy of Sciences and by a European Research Council (ERC) Starting Grant (European Union’s Horizon 2020 research and innovation program; grant 679146).
European Commission FP7 Network of Excellence (NoE) (282510)
WELLCOME TRUST (107630/Z/15/Z)
British Heart Foundation (RE/13/6/30180)
EC FP7 NOE (282510)
British Heart Foundation (RG/09/012/28096)
Embargo Lift Date
External DOI: https://doi.org/10.1016/j.stem.2016.10.019
This record's URL: https://www.repository.cam.ac.uk/handle/1810/262001
Attribution 4.0 International, Attribution 4.0 International, Attribution 4.0 International, Attribution 4.0 International